Patents by Inventor Gopi Kumar Mittapalli
Gopi Kumar Mittapalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002391Abstract: 4-Alkoxypyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).Type: ApplicationFiled: June 23, 2023Publication date: January 4, 2024Inventors: Gopi Kumar Mittapalli, Chi Ching Mak, Lewis Daniel Turner, Brian Joseph Hofilena, Ramkrishna Reddy Vakiti, Brian Walter Eastman, David Mark Wallace
-
Publication number: 20230312605Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer’s disease, diabetes, viral infections, and osteoarthritis).Type: ApplicationFiled: October 12, 2022Publication date: October 5, 2023Inventors: Gopi Kumar Mittapalli, Sunil Kumar KC, Chi Ching Mak, Brian Joseph Hofilena, Lewis Daniel Turner, Brian Walter Eastman, Ramkrishna Reddy Vakiti, Joseph Timothy Marakovits
-
Publication number: 20230286945Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: ApplicationFiled: November 18, 2022Publication date: September 14, 2023Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Gopi Kumar Mittapalli, Chandramouli Chiruta
-
Patent number: 11713320Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: December 30, 2020Date of Patent: August 1, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: Sunil Kumar Kc, Chi Ching Mak, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Brian Walter Eastman, Jianguo Cao, Chandramouli Chiruta, Venkataiah Bollu
-
Publication number: 20230192686Abstract: Pyrrolo[2,3-b]pyridine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,3-b]pyridine compound or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).Type: ApplicationFiled: October 12, 2022Publication date: June 22, 2023Inventors: Gopi Kumar Mittapalli, Sunil Kumar KC, Chi Ching Mak, Brian Joseph Hofilena, Chandramouli Chiruta, Venkataiah Bollu, Md Sharif Al Asad, Brian Walter Eastman
-
Patent number: 11673881Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: October 6, 2021Date of Patent: June 13, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: Sunil Kumar KC, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Joseph Timothy Marakovits, Chandramouli Chiruta, Chi Ching Mak, Jianguo Cao
-
Publication number: 20230167133Abstract: 7H-Pyrrolo[2,3-d]pyrimidine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 7H-pyrrolo[2,3-d]pyrimidine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).Type: ApplicationFiled: October 12, 2022Publication date: June 1, 2023Inventors: Gopi Kumar Mittapalli, Sunil Kumar KC, Chi Ching Mak, Brian Joseph Hofilena, Chandramouli Chiruta, Ramkrishna Reddy Vakiti, Brian Walter Eastman, Joseph Timothy Marakovits, Lewis Daniel Turner
-
Publication number: 20230104155Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: ApplicationFiled: October 6, 2021Publication date: April 6, 2023Inventors: Sunil Kumar KC, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Joseph Timothy Marakovits, Chandramouli Chiruta, Chi Ching Mak, Jianguo Cao
-
Patent number: 11548872Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: GrantFiled: January 22, 2021Date of Patent: January 10, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Gopi Kumar Mittapalli, Chandramouli Chiruta
-
Publication number: 20220402921Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: ApplicationFiled: December 30, 2020Publication date: December 22, 2022Inventors: Sunil Kumar KC, Chi Ching Mak, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Brian Walter Eastman, Jianguo Cao, Chandramouli Chiruta, Venkataiah Bollu
-
Publication number: 20220332698Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: ApplicationFiled: January 22, 2021Publication date: October 20, 2022Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Gopi Kumar Mittapalli, Chandramouli Chiruta
-
Patent number: 11174244Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: December 26, 2019Date of Patent: November 16, 2021Assignee: BioSplice Therapeutics, Inc.Inventors: Sunil Kumar KC, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Joseph Timothy Marakovits, Chandramouli Chiruta, Chi Ching Mak, Jianguo Cao
-
Patent number: 10947217Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: GrantFiled: December 4, 2019Date of Patent: March 16, 2021Assignee: Samumed, LLCInventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Gopi Kumar Mittapalli, Chandramouli Chiruta
-
Patent number: 10934297Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: February 22, 2019Date of Patent: March 2, 2021Assignee: Samumed, LLCInventors: Sunil Kumar Kc, Chi Ching Mak, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Brian Walter Eastman, Jianguo Cao, Chandramouli Chiruta, Venkataiah Bollu
-
Publication number: 20200339536Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: ApplicationFiled: December 26, 2019Publication date: October 29, 2020Inventors: Sunil Kumar KC, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Joseph Timothy Marakovits, Chandramouli Chiruta, Chi Ching Mak, Jianguo Cao
-
Publication number: 20200299263Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: ApplicationFiled: December 4, 2019Publication date: September 24, 2020Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Gopi Kumar Mittapalli, Chandramouli Chiruta
-
Patent number: 10759799Abstract: Indazole macrocycle compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: GrantFiled: June 13, 2019Date of Patent: September 1, 2020Assignee: Samumed, LLCInventors: Sunil Kumar K C, Gopi Kumar Mittapalli, Chandramouli Chiruta, Brian Joseph Hofilena
-
Patent number: 10744128Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: July 31, 2019Date of Patent: August 18, 2020Assignee: Samumed, LLCInventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Gopi Kumar Mittapalli
-
Patent number: 10703748Abstract: Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: October 31, 2018Date of Patent: July 7, 2020Assignee: Samumed, LLCInventors: Sunil Kumar Kc, Chi Ching Mak, Jianguo Cao, Venkataiah Bollu, Chandramouli Chiruta, Gopi Kumar Mittapalli, Brian Walter Eastman, Brian Joseph Hofilena
-
Patent number: 10669240Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: July 19, 2017Date of Patent: June 2, 2020Assignee: Samumed, LLCInventors: John Hood, Sunil Kumar KC, David Mark Wallace, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Chi Ching Mak, Venkataiah Bollu, Brian Eastman